Skip to content

Evaluating the efficacy and safety of Morodan and Huangqi in the treatment of chronic atrophic gastritis and gastric intestinal metaplasia: a prospective randomized controlled study

Evaluating the efficacy and safety of Morodan and Huangqi in the treatment of chronic atrophic gastritis and gastric intestinal metaplasia: a prospective randomized controlled study

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900025704
Enrollment
Unknown
Registered
2019-09-06
Start date
2019-09-10
Completion date
Unknown
Last updated
2019-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric intestinal metaplasia

Interventions

Moluodan:Morodan 1 bag (16 pills), 3 times a day, 30 minutes before meals, served with rice soup or warm water
6 months in total
Huangqi:Huangqi 1 bag at a time, two bags a day, soaking water for tea

Sponsors

Zhongda Hospital, Southeast University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Helicobacter pylori was positive previously. 13C breath test show that it's negative now and the gastroscopic pathology suggests chronic atrophic gastritis and/or gastric intestinal metaplasia. 2. Gastroscopic pathology suggests chronic atrophic gastritis and/or gastric intestinal metaplasia, and 13C breath test suggests Hp-negative patients. 3. Aged 18 to 70 years. 4. Those who are willing to complete relevant inspections and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Gastroscopy showed the presence of gastric dysplasia, gastric ulcer, gastric polyps, gastric cancer and other malignant tumors. History of gastric surgery; 2. Be allergic to the test drug; 3. There are other serious diseases of cardiovascular/pulmonary/brain; 4. Those need usage of NSAID or other anticoagulant drugs; 5. Pregnant women or during the Lactation.

Design outcomes

Primary

MeasureTime frame
Endoscopic and histopathological diagnosis;

Secondary

MeasureTime frame
Patient symptom score;Hematological indices;

Countries

China

Contacts

Public ContactRuihua Shi

Department of Gastroenterology, Zhongda Hospital, Southeast University

ruihuashi@126.com+86 13951799326

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026